# Enhancement of radiation effects by high-Z nanoparticles

R. C. Carrillo-Torres, R. Meléndrez, V. Chernov, M. Pedroza-Montero, R. García-Gutiérrez, M. Barboza-Flores



# Outline



- Motivation
- Radiotherapy
- Interaction of radiation with matter
- Dose enhancement by high-Z materials
- Gold nanoparticles
- Monte Carlo simulations
- In vitro studies
- In vivo studies
- Perspectives
- Conclusions
- Q&A

### **Motivation**



- High-Z nanoparticles as radiosensitizing agents to enhance the effectiveness of radiation therapy protocols.
- The basis of radiosensitization relies mainly on increasing photoelectric absorption cross-section relative to tissue.
- In spite of the strong development of this field of nanotechnology some of the results obtained in cells lines and animals are controversial making difficult to fully understand the radiation dose enhancing effects.
- We review the current developments in nanoparticles suitable for therapeutic applications. It will be shown that the potential efficacy of nanoparticles radiosensitization is highly sensitive to a number of physics and pharmacological parameters including irradiation energy and nanoparticle size, concentration, and intracellular localization.



- Radiotherapy (RT) has become one of the primary tools to treat and prevent the spread of abnormal cancerous cells.
- Slightly more than 50% of all patients who developed cancer will require RT at some stage of their illness.
- RT utilizes ionizing radiations and has been used for several decades to treat a wide variety of cancer types.

- Kilovoltage x-ray sources
  - Low penetration
  - Delivered high dose
  - Low skin sparing effect
- LINACs
  - Higher energy x-ray and electron beams in megavoltage range
  - Nowadays, most common sources of ionizing radiation
  - Improved in dose distribution and effectiveness of RT





- Particle radiotherapy
  - Less common due to high installation cost
  - Better dose concentration
  - Has a proven role in the management of orbital tumors such as base of skull sarcoma.
- Modern LINACs are able to perform sophisticated techniques:
  - Stereotactic radiosurgery (SRS)
  - Intensity modulated radiotherapy (IMRT)
  - Image-guided radiotherapy (IGRT)







- One of the greatest challenges in current radiotherapy is to provide a lethal dose only to a tumor within the tolerance of essential normal tissues. Devices like accelerator-based megavolt x-ray generators, tomotherapy machines, stereotactic radiotherapy systems and intensity modulated radiation therapy systems, are not sufficient to treat cancers because they fail to kill developed metastases outside the targeted volume.
- Use of radiosensitizers could compensate for the insufficiency of equipment-based treatment. Loading with gold nanoparticles (AuNPs) is one of the promising candidates in this area.

# Radiotherapy Safety

- Radiotherapy has unique features from the point of view of the potential for accidental exposure
- Consequences of accidental exposure can be very severe and affect many patients
- Careful clinical follow up may detect overdoses from about 10%
- A quality assurance programme is the key element in prevention of accidental exposure

# Few examples of RT mistakes

- In June, The Times reported that a Philadelphia hospital gave the wrong radiation dose to more than 90 patients with prostate cancer and then kept quiet about it. In 2005, a Florida hospital disclosed that 77 brain cancer patients had received 50 percent more radiation than prescribed because one of the most powerful and supposedly precise linear accelerators had been programmed incorrectly for nearly a year.
- <u>Dr. John J. Feldmeier</u>, a radiation oncologist at the University of Toledo and a leading authority on the treatment of radiation injuries, estimates that 1 in 20 patients will suffer injuries.
- Even though many accident details are confidential under state law, the records described 621 mistakes from 2001 to 2008. The Times found that on 133 occasions, devices used to shape or modulate radiation beams. On 284 occasions, radiation missed all or part of its intended target or treated the wrong body part entirely. In one case, radioactive seeds intended for a man's cancerous prostate were instead implanted in the base of his penis.

# Background

- During the period 1974-1976 the physicist failed to perform regular measurements (calibrations and QA)
- The physicist relied on estimations of the decay of the source to predict dose rate and calculate treatment time
- Rather than calculated decay, the physicist plotted dose rate on graph paper and extrapolated

### Impact of accident

- 426 patients received significant overdoses
- 11 were untraced 415 followed up
- 795 sites at risk identified
- 57% (243) died within the first year
- In 87 patients there was local control with no documented recurrence
- Survivors beyond the second year had an increased frequency of complications

When radiation interacts with matter, a number of processes can result...









The photoelectric effect: Ejects inner shell orbital electrons leaving a vacancy in the inner shell which is filled by an electron from an outer orbit releasing a characteristic xrays. These x-rays are absorbed locally by an orbital electron that will be emitted as Auger electron. The probability for photoelectric effects is proportional to  $(Z/E)^3$ . For high Z materials (such as gold) the interaction dominates at energies < 0.5 MeV while for tissues photoelectric effect is dominant at energies below 30 keV.

# **Biological damage**





Figure D-1: Mass attenuation coefficients for gold separated by interaction type



Figure D-2: Mass attenuation coefficients for tissue separated by interaction type

AuNPs contribute to enhanced generation of reactive oxygen species (ROS) like OH,  $O_2^{-}$ , and  ${}^{1}O_2^{-}$  under irradiations of x-rays in the diagnostic range. Enhanced generation of ROS by AuNPs under x-ray irradiation can be explained by the emission of photo- and Auger- electrons and fluorescent x-rays emitted in the interaction of incident x-rays with AuNPs. Generation of ROE may become additional contributors to tumor therapy in a novel photon-activated x-ray radiotherapy.



# **Biological damage**

![](_page_16_Picture_1.jpeg)

The interaction of ionizing radiation with biological matter result in the production of secondary electrons and free radicals, that will interact with other atoms and produce a chain of biological effects, like single and double strand breaks on DNA.

![](_page_16_Figure_3.jpeg)

![](_page_17_Picture_1.jpeg)

The damage by ionizing radiation to biological matter is usually quantified by using cell survival curves.

 Cell survival curves represent the relationship between the radiation dose and the proportion of cells that survive irradiation as measured in vitro.

The shape of the cell survival curves is dependent on factors such as the type or radiation and the cell line.

The shape of cell survival curve is usually described using radiobiological models and one of the most common models used is the linear quadratic model (LQ).

# **Cell survival curves**

![](_page_18_Picture_1.jpeg)

**Linear Quadratic Model** 

![](_page_18_Figure_3.jpeg)

![](_page_19_Picture_1.jpeg)

- Dose enhancement at interfaces between high and low Z materials has been studied for over 60 years. This effect caused burns and necrosis in tissue around reconstructive wires in mandibular cancer patients after RT.
- Then, Matsudaira et al. measured a radioenhancing effect of iodine contrast agent on cultured cells, demostrating the use of iodine as a radioenhancer in the 80's.
- Since then, there has been a considerable amount of reports of radiation enhancement studies using different materials like contrast agents (iodinated and gadolinium compounds), chemotherapy drugs (cis-platinum) and metallic nanostructures.

![](_page_20_Picture_1.jpeg)

- The research in radiation dose enhancing involves the search for materials and radiation sources that help us to improve the radiotherapy without causing (or minimizing) damage to healthy tissue.
- Distinct materials had been used to this goal like gadolinium and iodinated compounds, platinum and recently, gold nanoparticles, that is the main material discussed in this talk.
- There is a lot of papers that report Monte Carlo simulations, in vivo and in vitro assays that try to explain the phenomena and find the best parameters to optimize the dose enhancement effect.

![](_page_21_Picture_1.jpeg)

| Authors           | Year | Conclusions  |
|-------------------|------|--|
| Matsudaira et al. | 1980 | The influence of an iodine contrast medium on several responses to radiation was examined in mammalian cells in culture (L5178Y). The presence of the medium at the time of irradiation enhanced cell killing, frequency of micronuclei, and yield of DNA single-strand breaks induced by X rays, depending on the concentration used, whereas no such effect was found with $\gamma$ rays. It was concluded that the contrast medium sensitizes mammalian cells in culture primarily by means of the photoelectric effect, thereby increasing the absorbed dose of X rays in the cells.   |
| Santos et al.     | 1983 | The authors demonstrated the effect of iodine concentration and radiation quality on the dose enhancement in lymphocytes and calculate the effect of such effect on depth dose distributions in the brain after direct injection into rabbit brains. The combination of low-energy x-ray and contrast media is more effective than the agent alone in causing the regression of mouse tumors.  |
| lwamoto et al.    | 1987 | Loading tissue with iodine enhances the radiation dose absorbed from low-energy x-rays, as demonstrated by infusing radiographic contrast media into rabbits carrying VX-2 brain tumors and exposed to 15 Gy of 120 kVp x-rays. The dose enhancement was approximately 30% and the survival after tumor detection increased from 3 to 25.5 to 38.5 days for untreated rabbits, treated with radiation alone and radiation plus contrast media, respectively. The repeated infusion of 3.5 g kg <sup>-1</sup> of body weight did not affect renal function.   |
| Nath et al.       | 1990 | The dependence of iododeoxyuridine (IUdr) radiosensitization on photon energy and dose rate was investigated by irradiating Chinese hamster cells in vitro. The radiosensitization produced by 10 <sup>-5</sup> and 10 <sup>-4</sup> M IUdr for 28 keV photons from I-125, 60 keV photons from Am-241 and 830 keV photons from Ra-226. Radiosensitization factors (RF) were independent of dose rate from 0.3 to 0.73 Gy/h for all cases except for 10 <sup>-4</sup> M IUdR plus Am-241, in which case the RF increased from 2.5 to 3.0. In all cases, the RF decreased significantly as the dose rate was lowered from 0.30 to 0.17 Gy/h. Moreover, at 0.17 Gy/h the RF were essentially the same for all three photon energies. As the dose rate increased from 0.17 to 0.73 Gy/h, the difference between the RF for the three photon energies became larger; RF for Am-241 were higher than those for Ra-226 and I-125. |
| Rose et al.       | 1999 | This Phase I study was designed to evaluate the computed tomography (CT) scanner as a device for radiation therapy of human<br>brain tumors (CTRx) and to increase the therapeutic radiation dose to tumors compared to normal tissue by concentration of<br>infused contrast material in tumors. None of the patients showed adverse reactions to the CM or necrosis of the normal brain from<br>the CTRx boost radiation. Monte Carlo calculations of the radiation dose distributions in a model tumor showed that the CTRx<br>irradiation of tumors carrying 10 mg of iodine per gram of tumor was as good or better than the dose distribution from<br>conventional 10-MV X-rays. The treated tumor in two of the patients vanished after four treatments, whereas a control tumor in<br>one patient remained constant and grew 4-fold in another patient   |

![](_page_22_Picture_1.jpeg)

| Authors        | Year | Conclusions  |
|----------------|------|--|
| Robar et al.   | 2002 | This study examines the magnitude of tumor dose enhancement achieved by injection of gadolinium or iodine contrast media (CM) and treatment using modified x-ray photon spectra from linear accelerators. Monte Carlo modelling of the linear accelerator and patient geometry was used to explore the effect of removing the flattening filter for various beam qualities and the resultant effect on dose enhancement. Simulation results indicate that for flattened 6–24 MV photon beams and realistic CM tumor concentrations, the dose enhancement remains below 5%. However, if the flattening filter is removed, dose enhancement is increased significantly. For a 30 mg ml <sup>-1</sup> gadolinium CM tumor concentration, for example, 8.4%, 10.8%, 13.7% and 23.1% dose enhancements are achieved for 18 MV, 6 MV, 4 MV and 2 MV unflattened beams, respectively.   |
| Corde et al.   | 2004 | This study evaluates the optimal X-ray energy for increasing the radiation energy absorbed in tumors loaded with iodinated compounds. SQ20B human cells were irradiated with synchrotron monochromatic beam tuned from 32.8 to 70 keV. Two cell treatments were compared to the control: cells suspended in 10 mg ml <sup>-1</sup> of iodine radiological contrast agent or cells pre-exposed with 10 mM of IUdr for 48 h. Cells irradiated with both iodine compounds exhibited a radiation sensitization enhancement energy dependent, with a maximum at 50 keV. At this energy, the sensitization calculated at 10% survival was equal to 2.03 for cells suspended in iodinated contrast agent and 2.60 for IUdR. Cells pretreated with IUdR had higher sensitization factors over the energy range than for those suspended in iodine contrast agent. The survival curves presented no shoulder, suggesting complex lethal damages from Auger electrons. These results confirm the optimum energy at 50 keV. |
| Roeske et al.  | 2007 | Materials with atomic numbers (Z) ranging from 25 to 90 are considered in this analysis and the energy spectrum for a number of external beam x-ray sources and common radionuclides are evaluated. For a nanoparticle concentration of 5 mg/ml, the DEF is < 1.05 for Co-60, Ir-192, Au-198, Cs-137, 6, 18, and 25 MV x-rays for all materials considered. However, relatively large increases in the DEF are observed for 50, 80, 100, and 140 KVp x-rays as well as Pd-103 and I-125. The DEF increases for all sources as Z varies from 25-35. From Z = 40-60, the DEF plateaus or slightly decreases. For higher Z materials (Z>70), the DEF increases and is a maximum for the highest Z materials. High atomic number nanoparticles coupled with low energy external beam x-rays or brachytherapy sources offer the potential of significantly enhancing the delivered dose.  |
| Prezado et al. | 2009 | In this work, the dose enhancement factors and the peak to valley dose ratios (PVDRs) are assessed for different gadolinium (Z=64) concentrations in the tumor and different microbeam energies by using Monte Carlo simulations. A significant decrease in the PVDR values in the tumor, and therefore a relevant increase in the dose deposition, is found in the presence of gadolinium. The optimum energy for the dose deposition in the tumor while keeping a high PVDR in the healthy tissues, which guaranties their sparing, has been investigated.   |
| Townley et al. | 2012 | The authors report significant and controlled cell death using novel x-ray-activatable titania nanoparticles (NPs) doped with lanthanides.<br>Preferential incorporation of such materials into tumor tissue can enhance the effect of radiation therapy. Herein, the incorporation of<br>gadolinium into the NPs is designed to optimize localized energy absorption from a conventional medical x-ray. This result is further optimized by<br>the addition of other rare earth elements. Upon irradiation, energy is transferred to the titania crystal structure, resulting in the generation of<br>reactive oxygen species (ROS).  |

# **Gold nanoparticles**

![](_page_23_Picture_1.jpeg)

- Among the great variety of nanoparticle-based inorganic systems for biomedical applications, gold nanoparticles play an important role in cancer therapeutics.
- A great variety of these nanostructures had been used like:
  - Spherical nanoparticles
  - Nanorods
  - Nanocages
  - Nanoshells
  - Hollow gold nanospheres

![](_page_23_Picture_9.jpeg)

— 30 nm

Lim, Z. Z. J. et al. *Acta Pharmacol. Sin.* 2011, 32: 983-990. Jelveh, S. et al. *Cancers* 2011,3:1081-1110 Cobley, C. M. et al. *Chem. Soc. Rev.* 2011,40:44-56

![](_page_24_Picture_1.jpeg)

- These systems are highly effective platforms for theranostics agent, and have potential to:
  - Drug delivey
  - Cancer diagnostics
  - Photothermal and photodynamic therapy

![](_page_24_Figure_6.jpeg)

![](_page_25_Picture_1.jpeg)

The use of GNPs for biomedical applications is gaining popularity due to several reasons, mainly:

- Gold is considered to be relatively inert and therefore suitable for biomedical applications.
- Strong optical properties.
- Easily controllable surface chemistry, allowing flexible design and multifunctionality.
- Control over particle size and shape during synthesis.
- Gold absorbs ~3-times more than iodine at 20 and 100 keV.

### **Enhanced Permeability and Retention Effect**

![](_page_26_Picture_1.jpeg)

![](_page_26_Figure_2.jpeg)

Rapid vascularization in fastgrowing cancerous tissues is known to result in leaky, defective architecture and impaired lymphatic drainage. This structure allows an EPR effect, resulting in the accumulation of nanoparticles at the tumor site.

# Taking advantage of retention

**A.** Tumorous tissues suffer of Enhanced Permeability and Retention effect.

**B.** Nanoparticles injected in the blood stream do not permeate through healthy tissues.

**C.** Blood vessels in the surrounding of tumorous tissues are defective and porous.

**D.** Nanoparticles injected in the blood permeate through blood vessels toward tumorous tissues, wherein they accumulate.

Many preclinical studies have demonstrated gold nanoparticle (GNP) sensitization with kilovoltage radiation therapy. Monte Carlo modelling of GNP physical dose enhancement predicts sensitization at kilovoltage X-ray energies but not at clinically relevant megavoltage energies.

![](_page_29_Picture_1.jpeg)

#### Cho, S. (2005)

Based on the results of Hainfeld et al. (2004) simulated the dose enhancing using a modified phantom and tumor composition defined by ICRU to incorporate different concentrations of GNPs and compared 3 radiation sources.

| Concentration<br>(per gram of tumour) | 140 kVp | 6 MV FF | 6 MV NFF | 4 MV FF | 4 MV NFF |
|---------------------------------------|---------|---------|----------|---------|----------|
| 7 mg Au                               | 2.114   | 1.007   | 1.014    | 1.009   | 1.019    |
| 18 mg Au                              | 3.811   | 1.015   | 1.032    | 1.019   | 1.044    |
| 30 mg Au                              | 5.601   | 1.025   | 1.053    | 1.032   | 1.074    |

FF: flattening filter, NFF: no flattening filter.

![](_page_29_Figure_6.jpeg)

![](_page_30_Picture_1.jpeg)

![](_page_30_Figure_2.jpeg)

McMahon, S. J. et al. Phys. Med. Biol. 2008,53: 5635-5651

![](_page_31_Picture_1.jpeg)

![](_page_31_Figure_2.jpeg)

![](_page_32_Figure_1.jpeg)

![](_page_32_Figure_2.jpeg)

![](_page_33_Picture_1.jpeg)

![](_page_33_Figure_2.jpeg)

Ngwa, W. et al. Phys. Med. Biol. 2010,55: 6533-6548

![](_page_34_Picture_1.jpeg)

| Table 3. Rat               | io of mea  | n energy o  | ver mean i | range of esc    | aning ele | etrons (k       | $eV \mu m^{-1}$  | Au Au             | Jøer electrons Photoelectrons Characteristic x-rays Internaly absorbed |  |  |
|----------------------------|------------|-------------|------------|-----------------|-----------|-----------------|------------------|-------------------|--|--|--|
|                            | no or mea  | in energy o | ver mean i | Photon :        | source    | cuons (k        | ε <b>τ</b> μπ ). |                   | rameter to define a optimate   |  |  |
| C                          |            | Pd          | -103       |                 |           | ŀ               | -125             |                   |  |  |  |
| AuNP diameter (nm)         | 1.9        | 5           | 30         | 100             | 1.9       | 5               | 30               | 100               |  |  |  |
| CAuger and delta electrons | 8.54       | 8.46        | 7.73       | 7.50            | 8.56      | 8.50            | 7.74             | 7.48              | ubsequent dose enhancement   |  |  |
| a Photoelectrons           | 4.77       | 4.78        | 4.82       | 4.82            | 3.62      | 3.62            | 3.64             | 3.70              |  |  |  |
| All electrons              | 7.47       | 7.39        | 6.61       | 6.16            | 7.18      | 7.10            | 6.16             | 5.50              |  |  |  |
|                            |            | Yb          | -169       |                 |           | 30              | 0 kVp            |                   | trend demostrates that lower   |  |  |
| AuNP diameter (nm)         | 1.9        | 5           | 30         | 100             | 1.9       | 5               | 30               | 100               | respectively.  |  |  |
| Auger and delta electrons  | 7.00       | 6.89        | 6.10       | 5.61            | 4.63      | 4.58            | 4.02             | 3.56              | energy within proportionality and                                      |  |  |
| Photoelectrons             | 1.55       | 1.55        | 1.55       | 1.55            | 1.23      | 1.23            | 1.23             | 1.23              | shorter_ranges_than higher_energy                                      |  |  |
| All electrons              | 5.52       | 5.39        | 4.38       | 3.50            | 3.69      | 3.63            | 2.98             | 2.38              | <sup>2</sup> electrons.<br>3 keV) (1861 keV)                           |  |  |
|                            |            | Ir-         | 192        |                 | 6 MV      |                 |                  |                   | 67.55X 67.25X  |  |  |
| AuNP diameter (nm)         | 1.9        | 5           | 30         | 100             | 1.9       | 5               | 30               | 100               | $\times 10^{-8}$ 6.43 $\times 10^{-9}$ 30 nm s.r.x 100 nm 5.445        |  |  |
| Auger and delta electrons  | 4.74       | 4.67        | 4.13       | 3.63            | 5.60      | 5.56            | 4.85             | 4.28              | $\times 10^{-7}$ 1.17 $\times 10^{-7}$                                 |  |  |
| Photoelectrons             | 0.67       | 0.67        | 0.67       | 0.67            | 0.50      | 0.49            | 0.49             | 0.49              | $\times 10^{-3}$ 0.28 $\times 10^{-4}$ 45.25 42.18 47.88 47.88         |  |  |
| All electrons              | 3.61       | 3.54        | 2.81       | 2.10            | 4.12      | 4.07            | 3.18             | 2.35              | Worst case   |  |  |
| ionizations                |            | 2.49        | 10-8 2     | 05 10-8         | C.0C .    | 10-9            | 2 (0 10-         | 2.010             | $\times 10^{\circ}$ 9.28 $\times 10'$                                  |  |  |
|                            | u atom     | 3.48 ×      | 10 * 5.    | 05 × 10 °       | 6.06>     | < 10 -          | 5.60 × 10 ×      | 2. <del>4</del> % | Clinically infeasible  |  |  |
| The results pres           | enteo      | on Energ    | ris tistu  | <b>dythpr</b> o | Dwide     | enolim          | icallyrin        | elev              | antionsighteas to the effects of                                       |  |  |
| photon source e            | es, respe  | v and       | I GNF      | s size          | on ·      | the r           | ate of           | pho               | ptoelectric absorption and the ***                                     |  |  |
| Dose enhance               | ment       | asa         | functi     | on of           | GŇÞ       | size j          | was not          | ob                | served to be strictly  |  |  |
| propertional               | <b>GUN</b> | offeetu     | s ectre    | datend          | east      | y ran<br>be att | ributed          |                   |  |  |  |
| deneereneeren              | america    | d ahso      | rhed r     | nore re         | adilv     | withi           | n GNR            | of ind            |  |  |  |
|                            | 5 SCIP     | Babbo       | i beu i    |                 | uuny      | vvicin          |                  |                   |  |  |  |
|                            |            |             |            |                 |           |                 |                  |                   | 68.85N 66.85N 55.82N 96.15N  |  |  |

Lechtman, E. et al. Phys. Med. Biol. 2011,56: 4631-4647

![](_page_36_Picture_1.jpeg)

#### Herold et al. (2000)

They investigated dose enhancement and radiosensitization associated with electrons produced and scattered from gold microspheres suspended in cells *in vitro* irradiated with kilovoltage x-ray photons

![](_page_36_Figure_4.jpeg)

Herold, D. M. et al. Int. J. Radiat. Biol. 2000, 76: 1357-1364

#### Chien, C. C. et al. AIP Conf. Proc. 2007, 879: 1908-1911

### In vitro studies

Chien et al. (2007)

They synthesized 20 nm GNP by a synchrotron x-ray method and incubated CT-26 cells with it for 24h, subsequently they irradiated with electron from a linear accelerator with a beam energy of 6 MeV at various doses in a single fraction.

The GNPs tested in this report showed the cytotoxicity depended on the concentration of GNPs

The enhanced cell inhibition was more pronounced at higher radiation doses

![](_page_37_Figure_6.jpeg)

![](_page_37_Picture_7.jpeg)

• 0 mM

2

2

0.5 mM

3

0 mM ٠

2 mM

3

![](_page_38_Picture_1.jpeg)

![](_page_38_Figure_2.jpeg)

![](_page_39_Picture_1.jpeg)

![](_page_39_Figure_2.jpeg)

![](_page_40_Picture_1.jpeg)

#### RasenEnhanse (2009)

![](_page_40_Figure_3.jpeg)

![](_page_41_Picture_1.jpeg)

![](_page_41_Figure_2.jpeg)

photon energies: 160 kVp,

6MV and 15 MV..

Dose (Gy)

- Control

Dose (Gy)

GNP

0.01+

![](_page_42_Picture_1.jpeg)

![](_page_42_Figure_2.jpeg)

Note. REFs were calculated as the ratio of doses without GNPs/dose with GNPs at 10% survival.

![](_page_44_Picture_1.jpeg)

#### There are only a few *in vivo* reports of dose enhancing using gold nanoparticles:

 Hainfeld et al. (2004):
GNP on Balb/C mice bearing EMT-6 tumors injected with 1.9 nm GNP and exposed to 250 kVp x-rays

First *in vivo* experimentBig reduction of tumor

- volume
- Long term survival

- High GNP concentrations
- High radiation doses
- Short time between injection and irradiation

| Table 1. Biodistribu | ition of gold 5 min po | st i.v. injection          | injection of 1.35 g Au/kg.           |  |  |  |
|----------------------|------------------------|----------------------------|--------------------------------------|--|--|--|
|                      | % injected dose/g      | Tumour-to-<br>tissue ratio | Tumour periphery-<br>to-tissue ratio |  |  |  |
| Tumour               | $4.9 \pm 0.6$          | 1.0                        | 1.8                                  |  |  |  |
| Tumour periphery     | $8.9 \pm 3.2$          | 0.6                        | 1.0                                  |  |  |  |
| Muscle               | $1.4 \pm 0.1$          | 3.5                        | 6.4                                  |  |  |  |
| Liver                | $2.8 \pm 0.1$          | 1.8                        | 3.2                                  |  |  |  |
| Kidney               | $132.0 \pm 2.7$        | 0.4                        | 0.1                                  |  |  |  |
| Blood                | $18.6\pm3.7$           | 0.3                        | 0.5                                  |  |  |  |

![](_page_44_Figure_12.jpeg)

![](_page_44_Figure_13.jpeg)

• Chang et al. (2008):

GNP on C57BL/6 mice inoculated with mice melanoma B16F10 cells exposed to 13 nm GNP and 25 Gy of 6 MeV electron beams after 24 h incubation with GNP.

![](_page_45_Figure_3.jpeg)

In vitro clonogenic assay

![](_page_45_Picture_5.jpeg)

![](_page_45_Picture_6.jpeg)

- Tumor growth retarded
- Lower concentration of GNP than Hainfeld (2004)
- Longer time between injection and irradiation
- Significant increase in apoptosis
- Electron energies with clinical relevance.

![](_page_45_Picture_12.jpeg)

- Little effect in *in vitro* clonogenic assay
- Shorter survival time

![](_page_45_Picture_15.jpeg)

#### Alric et al. (2008):

They sinthesized GNP and functionalized it with Gd chelates to use it in x-ray imaging and radiotherapy.

They injected rats bearing 9L gliosarcoma tumors with 2.4 nm DTDTPA-GNP and irradiated with 83 keV synchrotron x-rays

- DTDTPA-GNP crossed the brain blood barrier.
- Moderate contrast enhancement (15%)
- The irradiated rats exhibit larger survival times than non-treated rats.
- Weak toxicity.
- Pioneer work that combine x-ray imaging and x-ray therapy

![](_page_46_Picture_10.jpeg)

Short time between injection and irradiation (20 min)

![](_page_46_Figure_12.jpeg)

![](_page_46_Figure_13.jpeg)

![](_page_46_Picture_14.jpeg)

![](_page_47_Picture_1.jpeg)

n value<sup>t</sup>

n value<sup>a</sup>

#### Hainfeld et al. (2010):

1.9 nm GNP in mice with radioresitant murine squamous cell carcinomas SCCVII irradiated with 68 keV synchrotron photons at different doses.

- Long-term tumor control using 68 keV at 42 Gy and 50.6 Gy
- Introduced hyperthermia (44°C for 20 min) to enhance radiation therapy

|                     | median (days)       | Traction bar tring | Praide   | Praide   |
|---------------------|---------------------|--------------------|----------|----------|
| A. 30 Gy, 68 keV    |                     |                    |          |          |
| -Gold               | 45                  | 1/7 (14%)          |          |          |
| +Gold               | 44                  | 1/7 (14%)          |          |          |
| 30 Gy, 68 keV(-Gold | d) versus 42 Gy, 68 | 8 keV(–Gold)       | p > 0.1  |          |
| 30 Gy, 68 keV(+Gold | l) versus 42 Gy, 68 | keV(+Gold)         | p < 0.02 |          |
| B. 42 Gy, 68 keV    |                     |                    |          |          |
| -Gold               | 53                  | 3/12 (25%)         |          |          |
| +Gold               | 76                  | 8/12 (67%)         |          |          |
| 42 Gy, 68 keV(-Gold | d) versus 42 Gy, 68 | 8 keV(+Gold)       |          | p < 0.04 |
| C. 44 Gy, 157 keV   |                     |                    |          |          |
| -Gold               | 29                  | 0/7 (0%)           |          |          |
| +Gold               | 31                  | 2/7 (29%)          |          |          |
| 44 Gy, 157 keV (-Ge | old) versus 44 Gy,  | 157 keV(+Gold)     | p < 0.05 |          |
| D. 50.6 Gy, 157 keV |                     |                    |          |          |
| -Gold               | 31                  | 0/8 (0%)           |          |          |
| +Gold               | 49                  | 3/8 (38%)          |          |          |
| 50.6 Gy, 157 keV(-g | old) versus 50.6 G  | y, 157 keV(+gold)  | p < 0.05 |          |

Median (days) Fraction surviving

![](_page_47_Picture_8.jpeg)

- No analysis of GNP tumor uptake or distribution
- High radiation doses

| A. Heat only   |                       | Median (days<br>7<br>Median (days | )                          | Surviving fraction<br>0/7 (0%)<br>Surviving fraction |   |  |  |
|--|-----------------------|-----------------------------------|----------------------------|--|---|--|--|
|  | Radiation alone       | Radiation +<br>heat               | Radiation +<br>heat + gold | Radiation alone                                      | Radiation +<br>heat                                 | Radiation +<br>heat + gold                         |  |
| B. 1 × 15 Gy<br>C. 1 × 23 Gy<br>D. 2 × 15 Gy<br>E. 1 × 30 Gy | 11<br>7.5<br>ND<br>45 | 25<br>38.5<br>18                  | 32<br>66<br>31.5<br>52     | 0/7<br>0/7<br>ND<br>1/7 (14%)                        | 1/10 (10%)<br>3/7 (43%)<br>8/20 (40%)<br>7/7 (100%) | 1/9 (11%)<br>3/6 (50%)<br>6/8 (75%)<br>11/14 (79%) |  |

![](_page_48_Picture_1.jpeg)

#### In vivo studies of GNP radiosensitization with ionizing radiation

| Author          | Year | GNP                                  | GNP dose   | Time to RT | Cell line         | Radiation | Dose     | Outcome<br>measure  | Group  | Outcome  | p-value |
|-----------------|------|--------------------------------------|--|------------|-------------------|-----------|----------|---|--|--|---------|
| Hainfeld et al. | 2004 | 1.9 nm                               | 0 g Kg <sup>-1</sup><br>1.35 g kg <sup>-1</sup><br>1.35 g kg <sup>-1</sup><br>2.7 g kg <sup>-1</sup> | 2 min      | EMT-6             | 256 kVp   | 26-30 Gy | Overall<br>survival 1<br>year                                       | GNP only<br>RT only<br>GNP+RT<br>GNP+RT                | 0%<br>20%<br>50%<br>86%  | 0.01    |
| Chang et al.    | 2008 | 13 nm                                | 0 g kg <sup>-1</sup><br>1 g kg <sup>-1</sup><br>0 g kg <sup>-1</sup><br>1 g kg <sup>-1</sup>         | 24 h       | B16F10            | 6 MeV     | 25 Gy    | Median<br>survival  | PBS<br>GNP<br>PBS+RT<br>GNP+RT                         | 45 days<br>40 days<br>60 days<br>80 days                             | <0.05   |
| Alric et al.    | 2008 | 2.4 nm<br>Au@DTDTPA-Gd <sub>50</sub> | Au 50.7 mM   | 20 min     | 9L<br>gliosarcoma | 83 keV    | ~460 Gy  | Mean<br>survival time<br>(MeST)<br>Median<br>survival time<br>(MST) | Control<br>Au@DTDTPA-Gd <sub>50</sub><br>+ irradiation | 17.5 days MeST<br>17.66 days MST<br>27.5 days MeST<br>33.25 days MST |         |
| Hainfeld et al. | 2010 | 1.9 nm                               | 0 g kg <sup>-1</sup><br>1.9 g kg <sup>-1</sup>   | ~1 min     | SCCVII            | 68 keV    | 30 Gy    | Doubling<br>time  | RT<br>RT+GNP   | 45 days<br>44 days   | <0.05   |
|                 |      |                                      |  |            |                   | 157 keV   | 42 Gy    |   | RT<br>RT+GNP   | 53 days<br>76 days   | <0.05   |
|                 |      |                                      |  |            |                   |           | 44 Gy    |   | RT<br>RT+GNP   | 29 days<br>31 days   |         |
|                 |      |                                      |  |            |                   |           | 50.6 Gy  |   | RT<br>RT+GNP   | 31 days<br>49 days   |         |

![](_page_49_Picture_1.jpeg)

### In vivo studies of GNP radiosensitization with ionizing radiation

Hainfeld studies showed the effective dose enhancement observed at the tumor sites.

The 68 keV and 157 keV photon beams showed improved tumor eliminating efficacy.

The 7 mg/kg gold concentration reported by Hainfeld, DEF values of over 1.60 were observed when using a 100 keV photon beam.

The effective dose enhancement dropped to 1.18 using a 250 keV photon beam and 1.05 when photon energy was increased to 500 keV.

The DEF values monotonically decreased as photon energy was increased and a minimum DEF of 1.003 was obtained using a 2.00 MeV photon beam.

![](_page_50_Picture_1.jpeg)

The main perspective for the use of nanostructures for biomedical applications is to design a non-toxic multifunctional structure capable of be used for diagnostic, imaging and therapy.

There are great advances in some techniques like photothermal ablation, photodynamic therapy and the use of magnetic particles that had demostrated to minimize the damage caused to healthy tissue.

![](_page_50_Figure_4.jpeg)

![](_page_51_Picture_1.jpeg)

![](_page_51_Figure_2.jpeg)

**Figure 2.** Spectral and photothermal properties of highly absorbing gold NRs compared with gold nanoshells. *A*, schematic of photothermal heating of gold NRs. The dimensions of gold NRs are tuned to have a near-IR plasmon resonance, at which point nanoparticle electrons resonantly oscillate and dissipate energy as heat. *B*, spectra for PEG-gold NRs (*red*) and PEG-gold nanoshells (*blue*), a benchmark for tunable plasmonic nanomaterials, at equal gold concentrations. *C*, *top*, rate of temperature increase for triplicate PEG-NR and PEG-gold nanoshell solutions (7 µg Au/mL, 810 nm laser, 2 W/cm<sup>2</sup>, *n* = 3 each). *Bottom*, IR thermographic image of PEG-NRs versus PEG-gold nanoshells after 2 min of irradiation. *Scale bar*, 5 mm. *D*, *in vitro* photothermal toxicity of PEG-NRs over human cancer cells in culture (MDA-MB-435). Tumor cells were incubated with PEG-NRs (14 µg/mL; *top*), PEG-nanoshells (14 µg/mL; *middle*), or media alone (*bottom*) and treated with laser irradiation (2 W/cm<sup>2</sup>, 810 nm, 5 min). Calcein AM staining indicates destruction of cells with PEG-NRs, whereas cells irradiated in the presence of nanoshells or media remained viable. Phase region of calcein staining inset. *Scale bar*, 10 µm.

![](_page_52_Picture_1.jpeg)

![](_page_52_Figure_2.jpeg)

Figure 4. Long circulation time, passive tumor targeting, and photothermal heating of passively targeted gold NR antennas in tumors. *A*, PEG-NRs were i.v. given (20 mg/kg) to three mice bearing MDA-MB-435 tumors, and blood was withdrawn over time to monitor clearance from circulation. *B*, PEG-NR biodistribution and targeting to MDA-MB-435 tumors 72 h after i.v. administration, quantified via ICP-MS (three mice). *T*, tumor; *Br*, brain; *Bl*, bladder; *M*, muscle; *H*, heart; *Lu*, lung; *K*, kidney; *Li*, liver; *SP*, spleen. Data are tabulated in Supplementary Table S1. *C*, PEG-NRs or saline were i.v. given (20 mg/kg) to mice bearing MDA-MB-435 tumors on opposing flanks. After NRs had cleared from circulation (72 h after injection), the right flank was irradiated using an 810-nm diode laser (2 W/cm<sup>2</sup>; beam size indicated by dotted circle). *D*, thermographic surveillance of photothermal heating in PEG-NR–injected (*top*) and saline-injected (*bottom*) mice.

![](_page_53_Picture_1.jpeg)

![](_page_53_Picture_2.jpeg)

BARTAT021911A2BA

![](_page_53_Picture_4.jpeg)

BARTAT021911A2BLL

![](_page_53_Picture_6.jpeg)

### Conclusions

![](_page_54_Picture_1.jpeg)

AuNPs are effective dose enhancers for superficial radiotherapy using kilovoltage x-ray beam and megavoltage electron beam.

The AuNPs enhanced the cells killing up to 15 times for 1 mMol/L of AuNPs irradiated with 80 kVp x-ray beams. Maximum dose enhancement factor (DEF) of 3 times was measured for 6 MeV electron beams in the presence of 1mMol/L AuNPs.

Minimal dose enhancement was observed for megavoltage photon beams which measured DEF are around 1 time (100% enhancement). Radiobiological analysis of the dose enhancement by AuNPs using linear quadratic model found systematic changes of alpha ( $\alpha$ ) value which increases with inclusion of AuNPs while there are very small changes for beta ( $\beta$ ) value.

Results of the studies on the AuNPs cytotoxicity for different concentrations and sizes were found to be minimal. Viability tests and cell morphology studies show no significant effects of AuNPs to the cells.

Finally, AuNPs can potentially be applied as a novel radiobiological dose enhancer for radiation therapy, synchrotron based microbeam and stereotactic radiotherapy.

### Thank you for your kind attention